Next Investors logo grey

ALA updated investor presentation


Published 06-SEP-2023 15:37 P.M.


38.9 seconds read

Shares Held: 16,196,579


Options Held: 0


Trust Centre

Our biotech Investment Arovella Therapeutics (ASX: ALA) just released an updated investor presentation.

Here are some slides that stood out to us:

1) On ALA’s partnership with $451M Imugene - In vivo data is due this half, meaning we could see the data from animal studies very soon.

2) ALA’s pathway to phase 1 firsts-in-human clinical trials in 2024 - this is significant especially because most cell therapy companies either do a deal or are acquired as they transition out of the pre-clinical stage.

ALA slide 2

Here is a slide showing some deals in the cell therapy industry - almost all of them are done at the pre-clinical/phase 1 stage.

Interestingly the most recent one was done between Precision Biosciences and Imugene which has already got an existing partnership with ALA in place.

ALA Slide 3

To check out the updated investor presentation click here or on the image below:

ALA Slide 4